Transphorm Releases Quality and Reliability Data Behind Recently Announced Device Shipment Numbers
Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified 650 V gallium nitride (GaN) semiconductors—today announced the industry’s first complete validation data set for GaN power FETs in the 600 V and higher range. This information expands on Transphorm’s December 2018 announcement indicating that the company has shipped over 250,000 GaN FETs to date. What follows provides details behind public Transphorm customer statements citing reliability as a major influencer behind their GaN device selection.
“In the power conversion market—quality, reliability, and performance are the three main factors used when vetting transistors. We’ve always operated with the mindset that prioritizing quality and reliability will result in high voltage GaN’s success,” explained Philip Zuk, Vice President of Technical Marketing Worldwide, Transphorm. “We’re proud to see that strategy deliver positive results and felt it important to release the validation data so that potential and existing customers can understand GaN’s true capabilities.”
Availability of the two new data types, Early Life Failure (ELF) and Field Failure, that round out the validation data set marks another major milestone for high voltage GaN technology. They further position Transphorm’s GaN reliability as competitive to and poised to likely surpass that of alternative solutions—Silicon and Silicon Carbide (SiC)—given that Transphorm’s power conversion technology is in its first maturation stage whereas Silicon transistors have long-since matured and SiC is a decade into its development.
High Voltage GaN Reliability: A Complete View
Transphorm’s complete data set includes five components of product reliability:
- Product Qualification: defined by JEDEC and AEC-Q101 Standards.
- Testing beyond standard requirements: includes high voltage switching, single event burnout (SEB), HTOL, and HTGB testing at elevated temperatures and voltages.
- Intrinsic Lifetime: measures device’s “wear-out” lifetime; also defines failure modes and acceleration factors.
- Extrinsic Lifetime or ELF: forecasts Field Failure rates in Failure in Time (FIT) or Parts per Million (ppm) per year rates; used for warranty calculations.
- Field Failure: measures device’s actual field performance in customer applications.
“Intrinsic data alone is not enough,” said Ron Barr, Vice President of Quality and Reliability, Transphorm. “Intrinsic testing gives us the acceleration factors that we use in conjunction with Early Life Failure testing to determine the product’s Infant Mortality rate. This makes it easy for customers to accurately vet GaN devices. Pairing intrinsic data with extrinsic data and Field Failure rates provides a complete baseline for how GaN FETs will perform.”
Extrinsic Early Lifetime Failure
Intrinsic failure rates give unrealistically optimistic views of product reliability. Also called Infant Mortality, ELF provides the most realistic view via FIT and ppm rates. Early Lifetime Failure assesses potential defects in materials, design, and process control that may cause parts to fail. Notably, ELF causes most customer warranty claims and typically occurs sooner and at higher rates than wear-out failures. Given this, customers use ELF data to determine warranty risks and costs.
- FIT: 0.45
- ppm: 4
Field Failure measures the number of devices that fail in customer systems in production in relation to the total number of parts sold. Transphorm has shipped over 250,000 FETs and accumulated over 1.3 billion field hours of operation resulting in the following Field Failure rates:
- FIT: 3.1
- ppm: 27.4 (conservative estimate)
Transphorm’s Field Failures align with that of SiC, which is reported to be less than 5 FIT. Further, Transphorm’s ppm rate continues to decrease over time regardless of application, suggesting that reliability is better than currently reported.
Read High Voltage GaN Switch Reliability for details on Transphorm’s ELF and Field Failure testing.
Intrinsic Lifetime is essentially a device’s theoretical lifetime assuming that material wear-out is the only contributor to the part’s longevity. The data is created using the “Physics of Failure” methodology, which involves measuring time to failure when stressing parts with voltage and temperature, and building related models used to predict ultimate lifetime.
Transphorm’s Intrinsic GaN wear-out:
- Mean Time Before Failure [MTBF]1: 1e11 hours [11M+ years]
- Lifetime2 [100 ppm]: 100M hours [11,415 years]
Transphorm designs, manufactures, and sells the highest performance, highest reliability GaN semiconductors for high-voltage power conversion applications. The company holds one of the largest Power GaN IP portfolios (1000+ issued and pending patents worldwide) and produces the industry’s only JEDEC and AEC-Q101 qualified GaN FETs. Website: www.transphormusa.com China Website: www.transphormchina.com
1 MTBF is the time when 63.2% of the population has failed
2 Lifetime is defined as the wear-out phase of the devices where 100 ppm/year is used
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Telna Launches New eSIM Solution at MWC Barcelona 201924.2.2019 00:00:00 | Pressemelding
Telna, a vertically integrated Network-as-a-Service (NaaS) provider of global end-to-end connectivity solutions, today is adding eSIM technology to its platform. The new resilient and efficient eSIM architecture will be showcased at Mobile World Congress Barcelona 2019, from February 25th - February 28th at Telna’s booth in Hall 1, Stand 1B80. “eSIM technology is another example of a global trend in digital transformation set to disrupt cellular connectivity,” says Gregory Gundelfinger, CEO of Telna. “Our customers now have access to both Consumer and IoT/M2M eSIM that is bundled with the rest of our software-defined network services.” eSIM is an embedded SIM card, meaning there is no physical SIM card and no physical swapping of SIM cards. It's easy to add data plans and is endorsed by the GSMA. “The virtualization of the SIM card removes one of the largest barriers when switching between networks, the physical SIM card,” says Gundelfinger. The Telna eSIM allows users to access their
Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00 | Pressemelding
Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00 | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te
Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00 | Pressemelding
Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented
Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00 | Pressemelding
Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is
Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00 | Pressemelding
Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of